TCB is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform. Harnessing the innate ability of GD-Ts has enabled TCB to develop a range of clinical-stage cell therapies designed to combat identified cancers and viral infections. TCB is embarking on phase II-into-pivotal (phase III) clinical studies, which are expected to commence in the fourth quarter of 2021, following United Kingdom and European Union regulations, with a view to launching its first oncology product, which will be for the treatment of acute myeloid leukemia (abbreviated as AML). The Company plans to conduct similar clinical trials in the United States in 2022 for the treatment of AML following an application to the FDA in H1 2022. Clinical results generated thus far have enabled TCB to obtain FDA orphan drug status for its method of treatment of AML. TCB is also developing an innovative range of genetically modified chimeric antigen receptor modified T cell (CAR-T) products for treatment of solid cancers.
Contact Us
Get in touch
Location
Room 27011, Albion Plaza, 2-6 Granville Road, Kowloon HK
Contact Us
Email : [email protected]
Our Hours
MON-FRI 09:00 – 19:00
SAT-SUN 10:00 – 14:00
Follow Us